PALO ALTO, Calif., June 17, 2015 (GLOBE NEWSWIRE) -- Carbylan Therapeutics (Nasdaq:CBYL), a specialty pharmaceutical company focused on the development of novel and proprietary combination therapies, today announced that David Renzi, President and Chief Executive Officer, is scheduled to present at the JMP Securities 2015 Life Sciences Conference, on Tuesday, June 23, 2015, at The St. Regis Hotel in New York, New York.
|Event:||JMP Securities 2015 Life Sciences Conference|
|Date:||Tuesday, June 23, 2015|
|Time:||2:00 p.m. ET|
An audio webcast of the Company's presentation will be available on the investor relations section of Carbylan's website at http://investor.carbylan.com. A replay of the presentation will be available for 90 days.
About Carbylan Therapeutics
Carbylan is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel and proprietary combination therapies that address significant unmet clinical needs. The Company's lead product candidate, Hydros-TA, is a proprietary, cross-linked combination of low dose corticosteroid and novel hyaluronic acid viscosupplement, designed to provide both rapid and sustained osteoarthritis pain relief via a single intra-articular injection.